Aethlon Medical, Inc. (AEMD) stock analysis
Healthcare · Medical Devices
From the 10-K filed 2026-06-10
How it makes money
It currently generates no revenue and relies on potential future commercialization of its medical device.
The company is a clinical-stage entity that has historically generated revenue only through government contracts, which are currently inactive. Its path to earning depends entirely on the successful development and regulatory approval of its Hemopurifier device, which aims to treat cancer and infectious diseases by removing specific particles from biological fluids.
What protects it: the moat
It asserts the Hemopurifier utilizes a proprietary lectin-based technology to bind and remove targeted pathogens and vesicles.
Management claims that its proprietary technology provides a functional advantage in binding to extracellular vesicles and viruses. However, the company does not detail specific patent portfolios or market-entry barriers that prevent competitors from developing similar filtration mechanisms.
What growth costs
It requires significant ongoing capital for clinical trials, regulatory approvals, and internal overhead costs.
Growth depends on funding expensive human studies to demonstrate safety and efficacy. These costs are exacerbated by personnel, laboratory material, and administrative infrastructure requirements, necessitating constant external financing.
What could damage it
A failure to maintain liquidity or secure continuous funding would force a termination of all research and development operations.
Because the company has no revenue and burns through cash to fund clinical studies, it depends on its ability to access equity or debt markets. If financing is unavailable, the company lacks the internal cash flow to sustain operations, leading to an immediate halt in development and potential business failure.
About Aethlon Medical, Inc.
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.